0
Communications to the Editor |

Clarification of Salmeterol Studies FREE TO VIEW

Harold S. Nelson, MD; Kathleen A. Rickard, MD
Author and Funding Information

Affiliations: National Jewish Medical and Research Center Denver, CO,  GSK Research and Development Research Triangle Park, NC

Correspondence to: Harold S. Nelson, MD, National Jewish Medical and Research Center, 1400 Jackson St, Denver, CO 80206.



Chest. 2003;123(3):965. doi:10.1378/chest.123.3.965
Text Size: A A A
Published online

To the Editor:

In a letter to the editor (June 2002),1Dr. Virchow questioned whether data from a recent article (August 2001)2were included in another published study.3 As authors of the referenced studies, we would like to confirm that the studies described were two separate studies, and data were not included from either study in the analysis of the other. In fact, the studies were conducted using different devices. The study by Nelson et al3 used the combination fluticasone/salmeterol dry powder inhaler, whereas the study by Fish et al2 used salmeterol powder as add-on therapy to the patients’ current inhaled steroid therapy.

Dr. Virchow also questions the entry requirement of > 12% reversibility in FEV1 with albuterol. A requirement for > 12%, or sometimes > 15%, reversibility is the standard in clinical asthma trials in the United States and has been required for participation in studies of inhaled corticosteroids and leukotriene pathwaymodifying agents as well as for bronchodilators. In fact, such an inclusion criteria was incorporated into a study conducted and reported by Dr. Virchow himself.4Additionally, the demonstration of > 12% reversibility is part of the definition of asthma, per the American Thoracic Society.5

References

Virchow, JC (2002) Salmeterol powder provides significantly better benefit than montelukast in asthmatic patients receiving concomitant therapy [letter].Chest121,2083-2084. [CrossRef]
 
Fish, JE, Israel, E, Murray, JJ, et al Salmeterol powder provides significantly better benefit than montelukast in asthmatic patients receiving concomitant inhaled corticosteroid therapy.Chest2001;120,423-430. [PubMed]
 
Nelson, HS, Busse, WW, Kerwin, E, et al Fluticasone proprionate/salmeterol combination provides more effective asthma control than low-dose inhaled corticosteroids plus montelukast.J Allergy Clin Immunol2000;106,1088-1095. [PubMed]
 
Virchow, JC, Prasse, A, Naya, I, et al Zafirlukast improves asthma control in patients receiving high-dose inhaled corticosteroids.Am J Respir Crit Care Med2000;162,578-585. [PubMed]
 
American Thoracic Society.. Lung function testing: selection of reference values and interpretative strategies.Am J Respir Crit Care Med1991;144,1202-1218
 

Figures

Tables

References

Virchow, JC (2002) Salmeterol powder provides significantly better benefit than montelukast in asthmatic patients receiving concomitant therapy [letter].Chest121,2083-2084. [CrossRef]
 
Fish, JE, Israel, E, Murray, JJ, et al Salmeterol powder provides significantly better benefit than montelukast in asthmatic patients receiving concomitant inhaled corticosteroid therapy.Chest2001;120,423-430. [PubMed]
 
Nelson, HS, Busse, WW, Kerwin, E, et al Fluticasone proprionate/salmeterol combination provides more effective asthma control than low-dose inhaled corticosteroids plus montelukast.J Allergy Clin Immunol2000;106,1088-1095. [PubMed]
 
Virchow, JC, Prasse, A, Naya, I, et al Zafirlukast improves asthma control in patients receiving high-dose inhaled corticosteroids.Am J Respir Crit Care Med2000;162,578-585. [PubMed]
 
American Thoracic Society.. Lung function testing: selection of reference values and interpretative strategies.Am J Respir Crit Care Med1991;144,1202-1218
 
NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.

  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543